TOP TEN perturbations for 39607_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39607_at
Selected probe(set): 204837_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39607_at (204837_at) across 6674 perturbations tested by GENEVESTIGATOR:
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):2.9418278Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 cell sample |
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):2.9184742Number of Samples:2 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated p53HCT116 cell sample |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.7152758Number of Samples:3 / 3
Experimental | influenza virus study 10 (A/H5N2) |
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.6622295Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/pH1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.6312351Number of Samples:3 / 3
Experimental | influenza virus study 11 (A/H5N3) |
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
ovarian tumor study 16 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):-2.2243872Number of Samples:3 / 5
Experimental | ovarian tumor study 16 |
Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM). | |
Control | normal ovarian surface epithelial cell sample |
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue. |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):2.0087814Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 DICER1(-/-) cell sample |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary)
Relative Expression (log2-ratio):-1.9386988Number of Samples:2 / 2
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, NOS of the soft tissue (subcutaneously implanted). |
rectal cancer study 2 (post; chemoradiotherapy) / rectal cancer study 2 (post; no therapy)
Relative Expression (log2-ratio):1.8806801Number of Samples:4 / 2
Experimental | rectal cancer study 2 (post; chemoradiotherapy) |
Tumor tissue samples obtained from the rectum of patients with rectal adenocarcinoma during a surgical resection, after a treatment with neoadjuvant concurrent (5-FU-based) chemoradiotherapy (CRT). The regimen of the neoadjuvant CRT was as follows: folinic acid 20mg/m2, 5-flurouracil (5-FU), 350mg/m2 d1-5, and d29-33 with 45 Gy in 25 fractions. Samples were collected after 6-8 weeks of completing the therapy. Patients were selected for neoadjuvant CRT based upon clinical and MRI staging features. Radiotherapy was CT planned, using a 3 field technique (posterior and two lateral fields), multileaf collimation and with patients having a full bladder during the radiotherapy. Patients were proven to be medically fit for treatment (WHO PS 0-2), with no significant medical co-morbidities, in particular no history of unstable or severe ischemic heart disease, and adequate renal (creatinine clearance >50ml/min) and liver function (billirubin <1.5 ULN, transaminases and alkaline phosphatase <2x ULN ). The staging was performed by clinical examination high resolution MRI of the pelvis (under anaesthesia at the discretion of the treating surgeon), and CT scan of the thorax and abdomen. Tumor stage was assigned according to TMN classification of UICC 6th edition 2002. | |
Control | rectal cancer study 2 (post; no therapy) |
Tumor tissue samples obtained during a surgical resection from the rectum of untreated (no pre-operative treated) patients with rectal adenocarcinoma.Tumor stage was assigned according to TMN classification of UICC 6th edition 2002. |
Duchenne muscular dystrophy study 5 (moderate) / normal vastus lateralis tissue
Relative Expression (log2-ratio):1.8672447Number of Samples:4 / 6
Experimental | Duchenne muscular dystrophy study 5 (moderate) |
Biopsies of vastus lateralis muscle from male patients with Duchenne muscular dystrophy and moderate fibrotic replacement. All subjects showed evidence of a dystrophic process (degeneration/regeneration of muscle fibers) and absence of dystrophin. | |
Control | normal vastus lateralis tissue |
Biopsies of vastus lateralis muscle from young adult volunteers. Samples were taken as normal controls from baseline samples of exercise experiments. |